{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:57:23Z","timestamp":1792421843801,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1053\/j.gastro.2018.11.022","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T11:56:35Z","timestamp":1542110195000},"page":"987-996.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"title":["Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events"],"prefix":"10.1053","volume":"156","author":[{"given":"Adeel A.","family":"Butt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashfaq","family":"Shuaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8735-1142","authenticated-orcid":false,"given":"Abdul-Badi","family":"Abou-Samra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obaid S.","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Freiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2018.11.022_bib1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.11.022_bib2","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.11.022_bib3","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.11.022_bib4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.11.022_bib5","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2018.11.022_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/liv.13027","article-title":"Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives","volume":"36","author":"Asselah","year":"2016","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2018.11.022_bib7","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/liv.13036","article-title":"Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES","volume":"36","author":"Butt","year":"2016","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2018.11.022_bib8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/hrt.2003.018937","article-title":"Evidence for association between hepatitis C virus seropositivity and coronary artery disease","volume":"90","author":"Vassalle","year":"2004","journal-title":"Heart"},{"key":"10.1053\/j.gastro.2018.11.022_bib9","first-page":"245","article-title":"Both hepatitis C virus and Chlamydia pneumoniae infection are related to the progression of carotid atherosclerosis in patients undergoing lipid lowering therapy","volume":"97","author":"Sawayama","year":"2006","journal-title":"Fukuoka Igaku Zasshi"},{"key":"10.1053\/j.gastro.2018.11.022_bib10","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1086\/507031","article-title":"No association between hepatitis C virus seropositivity and acute myocardial infarction","volume":"43","author":"Arcari","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2018.11.022_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2004.01.010","article-title":"Hepatitis B and C virus infection and the risk of atherosclerosis in a general population","volume":"174","author":"Volzke","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1053\/j.gastro.2018.11.022_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/599371","article-title":"Hepatitis C virus infection and the risk of coronary disease","volume":"49","author":"Butt","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2018.11.022_bib13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gutjnl-2017-313983","article-title":"The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection","volume":"67","author":"Mahale","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.11.022_bib14","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s10096-016-2692-y","article-title":"Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV\/HCV-coinfected patients who achieved sustained virological response","volume":"35","author":"Leone","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1053\/j.gastro.2018.11.022_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/hep.27766","article-title":"Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes","volume":"62","author":"Innes","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.022_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.11.022_bib17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.11.022_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ahj.2017.10.024","article-title":"Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients","volume":"198","author":"Cacoub","year":"2018","journal-title":"Am Heart J"},{"key":"10.1053\/j.gastro.2018.11.022_bib19","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.cgh.2013.01.023","article-title":"Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia","volume":"11","author":"Mohanty","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.11.022_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hep.28506","article-title":"Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES","volume":"64","author":"Simon","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.022_bib21","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s10620-015-3918-z","article-title":"Incidence and progression of chronic kidney disease after hepatitis C seroconversion: results from ERCHIVES","volume":"61","author":"Rogal","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2018.11.022_bib22","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/apt.13748","article-title":"Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES","volume":"44","author":"Butt","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.11.022_bib23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/apt.13837","article-title":"Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES","volume":"45","author":"Butt","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.11.022_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/cid\/cix359","article-title":"Risk of acute myocardial infarction among hepatitis C virus (HCV)-positive and HCV-negative men at various lipid levels: results from ERCHIVES","volume":"65","author":"Butt","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2018.11.022_bib25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/cid\/cix224","article-title":"Comparing Child-Pugh, MELD and FIB-4 to predict clinical outcomes in HCV-infected persons: results from ERCHIVES","volume":"65","author":"Butt","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2018.11.022_bib26","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"10.1053\/j.gastro.2018.11.022_bib27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/pds.2148","article-title":"Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study","volume":"20","author":"Lo Re","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1053\/j.gastro.2018.11.022_bib28","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2018.11.022_bib29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.6000\/1929-6029.2015.04.03.7","article-title":"Multiple imputation by fully conditional specification for dealing with missing data in a large epidemiologic study","volume":"4","author":"Liu","year":"2015","journal-title":"Int J Stat Med Res"},{"key":"10.1053\/j.gastro.2018.11.022_bib30","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.0006-341X.2000.00779.x","article-title":"Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests","volume":"56","author":"Robins","year":"2000","journal-title":"Biometrics"},{"key":"10.1053\/j.gastro.2018.11.022_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1541-0420.2010.01449.x","article-title":"Double inverse-weighted estimation of cumulative treatment effects under nonproportional hazards and dependent censoring","volume":"67","author":"Schaubel","year":"2011","journal-title":"Biometrics"},{"key":"10.1053\/j.gastro.2018.11.022_bib32","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1740774507081224","article-title":"Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study)","volume":"4","author":"Yoshida","year":"2007","journal-title":"Clin Trials"},{"key":"10.1053\/j.gastro.2018.11.022_bib33","first-page":"172","article-title":"Comparing marginal structural Cox proportional hazards models (MSCM) to standard methods for estimating causal effects of ART on the survival of HIV-infected patients in a regional referral hospital in western Kenya, 2011\u20132014","volume":"6","author":"Mutai","year":"2016","journal-title":"Int J Sci Res Publ"},{"key":"10.1053\/j.gastro.2018.11.022_bib34","first-page":"16","article-title":"Types and predictors of interferon\/ribavirin induced cardiac complications in the Egyptian patients with chronic hepatitis C virus","volume":"6","author":"El-Dosouky","year":"2016","journal-title":"J\u00a0Indian Coll Cardiol"},{"key":"10.1053\/j.gastro.2018.11.022_bib35","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/jac\/dkr202","article-title":"Treatment for hepatitis C virus with pegylated interferon-alpha plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients","volume":"66","author":"Masia","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1053\/j.gastro.2018.11.022_bib36","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/MEG.0b013e32833de92c","article-title":"Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-alpha-2a and\u00a0ribavirin","volume":"22","author":"Lange","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.11.022_bib37","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2018.11.022_bib38","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.2337\/diabetes.54.12.3541","article-title":"Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients","volume":"54","author":"Targher","year":"2005","journal-title":"Diabetes"},{"key":"10.1053\/j.gastro.2018.11.022_bib39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2018.02.015","article-title":"Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis","volume":"69","author":"Petta","year":"2018","journal-title":"J\u00a0Hepatol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508518352648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508518352648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:44:12Z","timestamp":1762163052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508518352648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0016508518352648"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2018.11.022","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2018.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the AGA Institute","name":"copyright","label":"Copyright"}]}}